Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...

Recursion Pharmaceuticals' stock has plummeted 57% since February, with significant failures in its lead drug REC-994 and other clinical candidates, raising concerns about its AI-driven drug discovery ...

After a year defined by pipeline cuts, the departure of its CEO and layoffs, Exscientia will merge into Recursion, creating one company that has 10 clinical readouts to look forward to over the next ...

Introduced with the Java 17 release, pattern matching enhances the instanceof operator so Java developers can better check and object's type and extract its components, and more efficiently deal with ...

Artificial intelligence (AI)-based drug developer Recursion said it has completed the fastest supercomputer to be wholly owned and operated by any pharmaceutical company worldwide, using technology ...

On the day before Thanksgiving 2020, the Amazon Kinesis data streaming service in AWS' main region US-East-1 went down for several hours. The company explained the outage in its subsequent failure ...

The much-anticipated video game designed by Jeppe Carlsen, the brain behind the puzzles in Limbo and Inside, seeks to deliver pleasurable moments of discovery. By Jason M. Bailey Long before the ...

This is shaping up to be a banner year for puzzle games, thanks to the likes of the superb Humanity and the brain-melting Viewfinder. Another one has just emerged on the release calendar in the form ...